sk&f-38393 has been researched along with Parkinsonian Disorders in 21 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " All rats separately underwent dose-response behavior testing for SKF38393 (0, 0." | 1.62 | Effects of intrastriatal injection of the dopamine receptor agonist SKF38393 and quinpirole on locomotor behavior in hemiparkinsonism rats. ( Chen, D; Guo, M; He, F; Jia, Q; Li, M; Li, Y; Sun, S; Sun, Y; Wang, M; Wang, X; Xiang, T; Yao, X; Zhang, X, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Kiessling, CY | 1 |
| Lanza, K | 1 |
| Feinberg, E | 1 |
| Bishop, C | 1 |
| Guo, M | 1 |
| Xiang, T | 1 |
| Li, M | 1 |
| Sun, Y | 1 |
| Sun, S | 1 |
| Chen, D | 1 |
| Jia, Q | 1 |
| Li, Y | 1 |
| Yao, X | 1 |
| Wang, X | 1 |
| Zhang, X | 1 |
| He, F | 1 |
| Wang, M | 1 |
| Andreoli, L | 1 |
| Abbaszadeh, M | 1 |
| Cao, X | 1 |
| Cenci, MA | 3 |
| Özkan, M | 1 |
| Johnson, NW | 1 |
| Sehirli, US | 1 |
| Woodhall, GL | 1 |
| Stanford, IM | 1 |
| Suárez, LM | 1 |
| Solís, O | 1 |
| Caramés, JM | 1 |
| Taravini, IR | 1 |
| Solís, JM | 1 |
| Murer, MG | 3 |
| Moratalla, R | 1 |
| Iderberg, H | 1 |
| Rylander, D | 1 |
| Bimpisidis, Z | 1 |
| Hyacinthe, C | 1 |
| Barraud, Q | 1 |
| Tison, F | 1 |
| Bezard, E | 3 |
| Ghorayeb, I | 1 |
| Farré, D | 1 |
| Muñoz, A | 1 |
| Moreno, E | 1 |
| Reyes-Resina, I | 1 |
| Canet-Pons, J | 1 |
| Dopeso-Reyes, IG | 1 |
| Rico, AJ | 1 |
| Lluís, C | 1 |
| Mallol, J | 1 |
| Navarro, G | 1 |
| Canela, EI | 1 |
| Cortés, A | 1 |
| Labandeira-García, JL | 1 |
| Casadó, V | 1 |
| Lanciego, JL | 1 |
| Franco, R | 1 |
| Xie, CL | 1 |
| Lin, JY | 1 |
| Wang, MH | 1 |
| Zhang, Y | 1 |
| Zhang, SF | 1 |
| Wang, XJ | 1 |
| Liu, ZG | 1 |
| Simola, N | 2 |
| Di Chiara, G | 1 |
| Daniels, WM | 1 |
| Schallert, T | 1 |
| Morelli, M | 3 |
| Ballion, B | 1 |
| Frenois, F | 1 |
| Zold, CL | 1 |
| Chetrit, J | 1 |
| Gonon, F | 1 |
| Lindgren, HS | 1 |
| Ohlin, KE | 1 |
| Faure, A | 1 |
| Leblanc-Veyrac, P | 1 |
| El Massioui, N | 1 |
| Tseng, KY | 1 |
| Riquelme, LA | 1 |
| Aubert, I | 1 |
| Guigoni, C | 1 |
| Håkansson, K | 1 |
| Li, Q | 1 |
| Dovero, S | 1 |
| Barthe, N | 1 |
| Bioulac, BH | 1 |
| Gross, CE | 2 |
| Fisone, G | 1 |
| Bloch, B | 1 |
| Goldberg, MS | 1 |
| Pisani, A | 1 |
| Haburcak, M | 1 |
| Vortherms, TA | 1 |
| Kitada, T | 1 |
| Costa, C | 1 |
| Tong, Y | 1 |
| Martella, G | 1 |
| Tscherter, A | 1 |
| Martins, A | 1 |
| Bernardi, G | 1 |
| Roth, BL | 1 |
| Pothos, EN | 1 |
| Calabresi, P | 1 |
| Shen, J | 1 |
| Carta, AR | 1 |
| Frau, L | 1 |
| Lucia, F | 1 |
| Pinna, A | 1 |
| Annalisa, P | 1 |
| Pontis, S | 1 |
| Silvia, P | 1 |
| Nicola, S | 1 |
| Schintu, N | 1 |
| Nicoletta, S | 1 |
| Micaela, M | 1 |
| Boraud, T | 1 |
| Bioulac, B | 1 |
| Carta, A | 1 |
| Fenu, S | 1 |
| Ni, Z | 1 |
| Gao, D | 1 |
| Bouali-Benazzouz, R | 1 |
| Benabid, AL | 1 |
| Benazzouz, A | 1 |
| Van De Witte, SV | 1 |
| Groenewegen, HJ | 1 |
| Voorn, P | 1 |
21 other studies available for sk&f-38393 and Parkinsonian Disorders
| Article | Year |
|---|---|
Dopamine receptor cooperativity synergistically drives dyskinesia, motor behavior, and striatal GABA neurotransmission in hemiparkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2020 |
Effects of intrastriatal injection of the dopamine receptor agonist SKF38393 and quinpirole on locomotor behavior in hemiparkinsonism rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Disease Models | 2021 |
Distinct patterns of dyskinetic and dystonic features following D1 or D2 receptor stimulation in a mouse model of parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Benzimida | 2021 |
Dopamine acting at D1-like, D2-like and α1-adrenergic receptors differentially modulates theta and gamma oscillatory activity in primary motor cortex.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adrenergic alpha-1 Receptor Agonists; Ad | 2017 |
L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Cerebral | 2014 |
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 8-Hydroxy-2-(di-n-propylamino)tetralin; | 2013 |
D1 receptor agonist improves sleep-wake parameters in experimental parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Disease M | 2014 |
Stronger Dopamine D1 Receptor-Mediated Neurotransmission in Dyskinesia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Caudate Nucleus; Corpus Striatu | 2015 |
Inhibition of Glycogen Synthase Kinase-3β (GSK-3β) as potent therapeutic strategy to ameliorates L-dopa-induced dyskinesia in 6-OHDA parkinsonian rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cyclic AMP-Dependent Protein Ki | 2016 |
Priming of rotational behavior by a dopamine receptor agonist in Hemiparkinsonian rats: movement-dependent induction.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Analysis of Variance; Animals; Apomorphi | 2009 |
D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Antiparkinso | 2009 |
Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aminoacetonitrile; Animals; Antiparkinso | 2009 |
Dopamine agonists increase perseverative instrumental responses but do not restore habit formation in a rat model of Parkinsonism.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Conditioning, | 2010 |
Impact of D1-class dopamine receptor on striatal processing of cortical input in experimental parkinsonism in vivo.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Cerebral Cortex; Corpus Striatu | 2004 |
Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2005 |
Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Age Factors; Animals; Behavior, Animal; | 2005 |
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Corpus St | 2008 |
Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 2001 |
Alterations in GAD67, dynorphin and enkephalin mRNA in striatal output neurons following priming in the 6-OHDA model of Parkinson's disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Dopamine Agonists; Down-Regulat | 2001 |
Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Apomorphine; | 2001 |
MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Disease Models, Animal; Dizocil | 2002 |